The Bridge Program Launch on June 8 was a great success, with approximately 80 people attending the event at Fishburners, Ultimo. Attendees were made up of 60 program participants, as well as a significant representation from the Collaboration members, and members of the press. The event was live-streamed for those unable to attend in person and was viewed from places around the world.
Transcript available upon request, contact firstname.lastname@example.org.
- Module 1: Sector Characteristics – Pathways and Players
- Module 2: Research Commercialisation Planning
- Module 3: Navigating Regulatory and Reimbursement Pathways
- Module 4: Entrepreneurial Skills to Optimise Commercialisation
Occasional Seminar Series
Rob McInnes, DibbsBarker:
Preparing for pharma and life sciences deal making – know what you want and how to negotiate for it.
Professor Maree Smith, University of Queensland:
University commercialisation approaches and how this can translate research.
Professor Frank Gannon, QIMR Berghofer Medical Research Institute:
Wealth from medical research.
The residential training component of the Bridge Program ran from 21 – 23 October 2017, and built on the foundation of knowledge gained by the program participants during the previous 4 months of online training. These online modules covered a range of topics including sector characteristics – pathways and players; research commercialisation planning; navigating regulatory and reimbursement pathways; and entrepreneurial skills to optimise commercialisation.
During the residential training component eighty-nine program participants gained from exposure to senior representatives from more than twenty industry organisations, including pharmaceutical companies operating globally including AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Janssen, MSD, Mundipharma, Novartis and Pfizer.
Participants were taken on a three-part journey from ‘how the global pharmaceutical industry discovers and develops drugs’, to ‘bench to biotech’, and finished with ‘biotech to patient’ throughout the residential training component.
Program delivery included presentations from prominent speakers from the pharmaceutical industry, as well as academics and others government and other parts within the sector. These presentations varied from providing insights into the pharmaceutical development pathway to case studies and reflections from those that have been through the process. The presentations were complemented by panel sessions where program participants were able to interact directly with expert panellists from both Australia and overseas.
In addition to the presentations and panel sessions, was an overarching Biotech Commercialisation and Collaboration Experience – an interactive simulation activity where program participants were put into product research teams, overseeing a fictional start-up with an early stage pharmaceutical. Over the three-day program, the product research teams were provided with opportunities to pitch to the pharmaceutical companies in the Bridge Program.
The inaugural Bridge Program officially came to a close on 27 November 2017 with program participants attending a closing ceremony at QUT’s Room three sixty in Brisbane.